Wockhardt Pharma has delivered a strong improvement in Q1 FY27, with revenue rising 25.9% YoY to ₹929 crore and net profit reaching about ₹107 crore, compared with a loss in the year-ago quarter; operating profit also jumped sharply to around ₹192 crore. The biggest long-term trigger is Zaynich (Zidebactam/Cefepime), Wockhardt’s novel antibiotic for serious drug-resistant bacterial infections. The drug has received USFDA approval, while the company is pursuing launches in other markets, creating the potential for a new high-value revenue stream. Wockhardt itself has highlighted Zaynich as a key driver of its next growth phase and is targeting substantial global sales potential. The company has also received CDSCO approval for Zaynich in India for complicated urinary-tract infections, strengthening its commercialisation opportunity. Another positive is Wockhardt's strategic shift away from its loss-making US generics business toward novel antibiotics, innovation and higher-value products, which could improve profitability over time

#TechnicalViews

491 likes·74 comments